Gilead Sciences is a global leader in antiviral and oncology therapies and one of the world's leading biotechnology companies.

Gilead Sciences generated $29.4 billion in revenue in 2025, growing approximately 2% year-over-year, with its commercial portfolio anchored by its HIV franchise — Biktarvy is the world's most prescribed HIV treatment — and a growing oncology business built through the acquisition of Immunomedics (Trodelvy ADC) and Kite Pharma (axicabtagene ciloleucel CAR-T). Lenacapavir — a twice-yearly injectable HIV treatment — demonstrated 100% efficacy in preventing HIV in women in the PURPOSE 1 trial in 2024, potentially the most significant HIV prevention advance since the introduction of PrEP. Gilead's hepatitis C franchise, which transformed that disease from a chronic condition to a curable infection, continues to generate significant revenue despite market maturation.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.

Topics Covered
• Financial performance 2023-2025
• SWOT analysis
• Technological know-how and platform capabilities
• Latest products, pipeline, and R&D programs
• M&A and partnership activity 2023-2025
• Marketing tactics and commercial strategy
• Organization and management